Levin Capital Strategies L.P. Has $262,000 Stake in Delcath Systems, Inc. (NASDAQ:DCTH)

Levin Capital Strategies L.P. grew its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 12.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,969 shares of the company’s stock after buying an additional 5,969 shares during the quarter. Levin Capital Strategies L.P. owned approximately 0.20% of Delcath Systems worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. AIGH Capital Management LLC acquired a new stake in shares of Delcath Systems in the 4th quarter valued at $4,918,000. ADAR1 Capital Management LLC acquired a new position in Delcath Systems during the 4th quarter worth about $962,000. Worth Venture Partners LLC acquired a new position in Delcath Systems during the 4th quarter worth about $1,224,000. Vivo Capital LLC lifted its position in Delcath Systems by 94.9% during the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock worth $7,950,000 after buying an additional 811,555 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Delcath Systems by 31.0% during the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after buying an additional 161,678 shares in the last quarter. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on DCTH shares. Craig Hallum initiated coverage on Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 price target for the company. HC Wainwright lifted their price objective on shares of Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Finally, Stephens started coverage on Delcath Systems in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price for the company. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.83.

Delcath Systems Price Performance

Shares of Delcath Systems stock traded up $0.15 on Wednesday, reaching $8.62. 174,771 shares of the company’s stock were exchanged, compared to its average volume of 239,737. Delcath Systems, Inc. has a 52 week low of $2.25 and a 52 week high of $9.18. The firm’s 50-day moving average is $7.77 and its two-hundred day moving average is $5.86.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.43). The firm had revenue of $3.14 million during the quarter, compared to the consensus estimate of $3.70 million. Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. On average, equities analysts predict that Delcath Systems, Inc. will post -1.31 earnings per share for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.